rivastigmine has been researched along with scopolamine hydrobromide in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (21.74) | 18.2507 |
| 2000's | 8 (34.78) | 29.6817 |
| 2010's | 9 (39.13) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chaudhaery, SS; Nath, C; Nazir, A; Roy, KK; Sammi, SR; Saxena, AK; Saxena, G; Shakya, N | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Demura, N; Fukaya, H; Iimura, A; Ohara, T; Seno, N; Tanaka, K | 1 |
| Bass, R; Chen, Y; Shohami, E; Weinstock, M | 1 |
| Chen, Y; Constantini, S; Shohami, E; Weinstock, M | 1 |
| Ballard, TM; McAllister, KH | 1 |
| Bejar, C; Wang, RH; Weinstock, M | 2 |
| Fischer, P | 1 |
| Bermudez, I; Groot-Kormelink, PJ; Smulders, CJ; van Kleef, RG; Vijverberg, HP; Zwart, R | 1 |
| Driguès, N; Sagi, Y; Youdim, MB | 1 |
| Deiana, S; Harrington, CR; Riedel, G; Wischik, CM | 1 |
| Appenroth, D; Decker, M; Fleck, C; Lehmann, J | 1 |
| Chen, HZ; Cui, YY; Li, J; Shao, BY; Song, MK; Wang, H; Xia, Z; Xu, ZP; Zhang, WW | 1 |
| Chavhan, SS; Joshi, SA; Sawant, KK | 1 |
| Mishra, DN; Nagpal, K; Singh, SK | 1 |
| Gawel, K; Jenda, M; Kotlinska, JH; Labuz, K; Silberring, J | 1 |
| Ahnaou, A; Drinkenburg, WH; Huysmans, H; Jacobs, T | 1 |
| Gawel, K; Gibula-Bruzda, E; Jenda, M; Kotlinska, JH; Labuz, K; Marszalek-Grabska, M; Silberring, J | 1 |
| Baptista T, T; Piñero A, J; Ramírez V, J; Sandia S, I | 1 |
| Borah, A; Dutta, A; Gothwal, A; Gupta, U; Jain, SK; Singh, H | 1 |
| Arumugam, K; Bojja, SL; Kumar, N; Rao, CM; Rompicherla, SKL | 1 |
1 review(s) available for rivastigmine and scopolamine hydrobromide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
22 other study(ies) available for rivastigmine and scopolamine hydrobromide
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology.
Topics: Acetylcholinesterase; Administration, Oral; Animals; Avoidance Learning; Caenorhabditis elegans; Carbamates; Catalytic Domain; Cholinesterase Inhibitors; Databases, Factual; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Male; Mice; Models, Molecular; Nootropic Agents; Quantitative Structure-Activity Relationship; Scopolamine | 2010 |
SDZ ENA 713 facilitates central cholinergic function and ameliorates spatial memory impairment in rats.
Topics: Animals; Basal Ganglia; Behavior, Animal; Brain Chemistry; Carbamates; Choline O-Acetyltransferase; Cholinergic Antagonists; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Male; Memory Disorders; Microdialysis; Parasympathetic Nervous System; Phenylcarbamates; Rats; Rats, Wistar; Rivastigmine; Scopolamine; Space Perception | 1997 |
Cerebro-protective effects of ENA713, a novel acetylcholinesterase inhibitor, in closed head injury in the rat.
Topics: Animals; Blood-Brain Barrier; Body Temperature; Brain Edema; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Head Injuries, Closed; Hippocampus; Male; Movement; Phenylcarbamates; Rats; Reflex; Rivastigmine; Scopolamine | 1998 |
Rivastigmine, a brain-selective acetylcholinesterase inhibitor, ameliorates cognitive and motor deficits induced by closed-head injury in the mouse.
Topics: Animals; Brain Edema; Carbamates; Cholinergic Antagonists; Cholinesterase Inhibitors; Cognition Disorders; Head Injuries, Closed; Male; Maze Learning; Mecamylamine; Memory; Mice; Movement; Movement Disorders; Muscarinic Antagonists; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Scopolamine | 1998 |
The acetylcholinesterase inhibitor, ENA 713 (Exelon), attenuates the working memory impairment induced by scopolamine in an operant DNMTP task in rats.
Topics: Animals; Carbamates; Cholinesterase Inhibitors; Conditioning, Operant; Dose-Response Relationship, Drug; Male; Memory; Neuroprotective Agents; Phenylcarbamates; Rats; Reaction Time; Rivastigmine; Scopolamine | 1999 |
Effect of rivastigmine on scopolamine-induced memory impairment in rats.
Topics: Animals; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Corpus Striatum; Drug Therapy, Combination; Hippocampus; Male; Maze Learning; Memory; Muscarinic Antagonists; Muscle, Skeletal; Phenylcarbamates; Rats; Rats, Sprague-Dawley; Rivastigmine; Scopolamine; Tacrine | 1999 |
Gender differences in the effect of rivastigmine on brain cholinesterase activity and cognitive function in rats.
Topics: Animals; Brain; Carbamates; Cholinesterase Inhibitors; Cholinesterases; Female; Male; Memory; Memory Disorders; Muscarinic Antagonists; Muscle, Skeletal; Myocardium; Orchiectomy; Ovariectomy; Phenylcarbamates; Physostigmine; Rats; Rats, Sprague-Dawley; Rivastigmine; Scopolamine; Sex Factors | 2000 |
Successful treatment of nonanticholinergic delirium with a cholinesterase inhibitor.
Topics: Aged; Carbamates; Cholinesterase Inhibitors; Delirium; Female; Humans; Muscarinic Antagonists; Phenylcarbamates; Rivastigmine; Scopolamine | 2001 |
Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism.
Topics: Acetylcholine; Alkaloids; Animals; Atropine; Azocines; Binding, Competitive; Cholinergic Agents; Cholinesterase Inhibitors; Dichlorvos; Dose-Response Relationship, Drug; Female; Galantamine; Humans; Membrane Potentials; Models, Biological; Nicotine; Oocytes; Phenylcarbamates; Physostigmine; Plasmids; Quinolizines; Receptors, Nicotinic; Rivastigmine; Scopolamine; Tacrine; Xenopus laevis | 2005 |
The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats.
Topics: Animals; Basal Ganglia; Behavior, Animal; Carbamates; Cholinesterase Inhibitors; Dopamine; Hippocampus; Hyperkinesis; Indans; Levodopa; Lewy Body Disease; Male; Monoamine Oxidase Inhibitors; Motor Activity; Muscarinic Antagonists; Norepinephrine; Phenylcarbamates; Rats; Rats, Sprague-Dawley; Rivastigmine; Scopolamine; Serotonin; Time Factors; Tranylcypromine; Tryptophan | 2005 |
Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine.
Topics: Animals; Cholinesterase Inhibitors; Cognition Disorders; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Female; Maze Learning; Memory; Methylene Blue; Mice; Muscarinic Antagonists; Nootropic Agents; Phenylcarbamates; Postural Balance; Rivastigmine; Scopolamine; Space Perception; Swimming | 2009 |
A new way of data interpretation for cognition tests in rats used to characterise six choline esterase inhibitors with heterocyclic nitrogen bridgehead structure. Application in Alzheimer therapy.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Cognition; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Exploratory Behavior; Female; Heterocyclic Compounds; Maze Learning; Memory; Muscarinic Antagonists; Nootropic Agents; Phenylcarbamates; Psychomotor Performance; Rats; Rats, Wistar; Rivastigmine; Scopolamine | 2008 |
Peripheral cholinoceptor antagonist anisodamine counteracts cholinergic adverse effects and facilitates cognitive amelioration of rivastigmine.
Topics: Animals; Avoidance Learning; Cholinergic Antagonists; Cognition; Cognition Disorders; Drug Therapy, Combination; Intestines; Male; Mice; Mice, Inbred Strains; Muscle Cramp; Neuroprotective Agents; Peripheral Nervous System Diseases; Phenylcarbamates; Random Allocation; Rivastigmine; Salivation; Scopolamine; Solanaceous Alkaloids | 2009 |
Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies.
Topics: Amnesia; Animals; Biological Transport; Brain; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Enbucrilate; Lactic Acid; Maze Learning; Mice; Nanoparticles; Neuroprotective Agents; Particle Size; Phenylcarbamates; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rivastigmine; Scopolamine | 2010 |
Optimization of brain targeted chitosan nanoparticles of Rivastigmine for improved efficacy and safety.
Topics: Amnesia; Animals; Behavior, Animal; Body Weight; Brain; Chitosan; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Evaluation, Preclinical; Factor Analysis, Statistical; Male; Maze Learning; Memory; Mice; Nanoparticles; Neuroprotective Agents; Phenylcarbamates; Polysorbates; Rats; Rivastigmine; Scopolamine; Treatment Outcome | 2013 |
Influence of cholinesterase inhibitors, donepezil and rivastigmine on the acquisition, expression, and reinstatement of morphine-induced conditioned place preference in rats.
Topics: Animals; Cholinesterase Inhibitors; Conditioning, Psychological; Donepezil; Drug-Seeking Behavior; Indans; Male; Mecamylamine; Morphine; Motor Activity; Muscarinic Antagonists; Narcotics; Nicotinic Antagonists; Phenylcarbamates; Piperidines; Rats, Wistar; Rivastigmine; Scopolamine; Space Perception | 2014 |
Cortical EEG oscillations and network connectivity as efficacy indices for assessing drugs with cognition enhancing potential.
Topics: Animals; Cerebral Cortex; Cognition; Donepezil; Drug Evaluation, Preclinical; Electrodes, Implanted; Electroencephalography; Galantamine; Gamma Rhythm; Indans; Male; Memantine; Motor Activity; Muscarinic Antagonists; Neural Pathways; Nootropic Agents; Phenylcarbamates; Piperidines; Principal Component Analysis; Rats, Sprague-Dawley; Rivastigmine; Scopolamine; Signal Processing, Computer-Assisted; Tacrine; Theta Rhythm | 2014 |
Acquisition and reinstatement of ethanol-induced conditioned place preference in rats: Effects of the cholinesterase inhibitors donepezil and rivastigmine.
Topics: Animals; Cholinesterase Inhibitors; Conditioning, Psychological; Donepezil; Ethanol; Indans; Male; Mecamylamine; Muscarinic Antagonists; Nicotinic Antagonists; Piperidines; Rats; Rats, Wistar; Receptors, Nicotinic; Reinforcement, Psychology; Rivastigmine; Scopolamine | 2016 |
Treating 'Devil׳s Breath׳ intoxication: Use of rivastigmine in six patients with toxic psychoses due to non pharmaceutical scopolamine.
Topics: Adolescent; Antipsychotic Agents; Cholinesterase Inhibitors; Female; Humans; Illicit Drugs; Male; Psychiatric Status Rating Scales; Psychoses, Substance-Induced; Rivastigmine; Scopolamine; Treatment Outcome | 2017 |
Behavioral and Biochemical Implications of Dendrimeric Rivastigmine in Memory-Deficit and Alzheimer's Induced Rodents.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Brain; Bridged-Ring Compounds; Disease Models, Animal; Drug Combinations; Maze Learning; Memory Disorders; Mice; Motor Skills; Organometallic Compounds; Polysaccharides; Rats; Rats, Wistar; Rivastigmine; Rotarod Performance Test; Scopolamine; Spatial Memory | 2019 |
Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease.
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Area Under Curve; Biological Availability; Cholinesterase Inhibitors; Colchicine; Disease Models, Animal; Liposomes; Male; Maze Learning; Memory Disorders; Models, Biological; Nanoparticles; Rats; Rats, Wistar; Rivastigmine; Scopolamine | 2021 |